BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

WuXi Biologics Reports Remarkable 2022 Annual Results

2022 Financial Highlights Revenue: The Group's revenue increased to RMB15,268.7 million with an increase of 48.4% y-o-y. The increase was...

March 23, 2023 | News

3SBio Reports 7.5% YoY Revenue Growth and 25.2% Jump in Profit for 2022

New drugs started to embrace a commercialization wave, and license-out and license-in partnerships geared up. Revenue in 2022 increased by 7.5% year on yea...

March 22, 2023 | News

AXA Mind Health Study reveals more than half of Gen Z in Asia are suffering from poor mental health

While the COVID-19 pandemic has taken a heavy toll on mind health across society, the latest findings from the annual AXA Study of Mind Health and Wel...

March 20, 2023 | News

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results

Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial r...

March 15, 2023 | News

Akeso, based in Hong Kong, completes patient enrollment for Phase III clinical trial of Cadonilimab in the treatment of gastric cancer.

Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-sp...

March 14, 2023 | News

Antengene's ATG-022 Phase I CLINCH Trial for Solid Tumor Treatment Receives IND Approval in China

- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Assoc...

March 14, 2023 | News

Prenetics Forms Advisory Board for Precision Oncology Strategy

Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Adviso...

March 02, 2023 | News

Keymed and Lepu Biopharma gain global exclusive license for CMG901 from AstraZeneca.

CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors. Preliminary results from the Phase 1 trial indicat...

February 24, 2023 | News

Recce Pharmaceuticals Announces RECCE® Trademark Registered in Hong Kong

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced that it has ...

February 03, 2023 | News

Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers

Based on positive clinical readouts from a Phase IIb study for isSCC and a Phase II study for BCC, Sirnaomics is formulating a communication package for th...

February 02, 2023 | News

Agilis RoboticsTM Completes New Round of Live Animal Trials with Miniaturized Robotic Instruments for Endoscopic Surgery

Dr. Jason Y.K. Chan, the co-founder of Agilis RoboticsTM , conducted the test with the firm's second-generation device on a live pig specimen and...

January 17, 2023 | News

MGI Demonstrates Strong Commitment to Expanding Genomic Access in Europe

With a commitment to building core tools and technology to lead life science, MGI Tech Co., Ltd. (or its affiliates, referred to as "MGI") is dedicated to ...

January 16, 2023 | News

Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023

Rade Drmanac, PhD, Chief Scientific Officer, announced "free three-month trial" program and "reagent rental leasing" program, giving customers the opportun...

January 11, 2023 | News

Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit "Named Patients" in Hong Kong

Luye Pharma has signed an agreement with Abacus Medicine Pharma Services (AMPS), an international healthcare and pharmaceutical services company, the terms...

January 10, 2023 | News

Stay Connected